Nktx stock forecast.
Nov 29, 2023 · 2 brokers have issued twelve-month target prices for Nutex Health's stock. Their NUTX share price targets range from $1.50 to $3.00. On average, they expect the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 927.4% from the stock's current price.
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...The 8 analysts offering 1 year price forecasts for NKTX have a max estimate of — and a min estimate of —. Analyst rating Based on 10 analysts giving stock ratings to NKTX in the past 3 months.28 thg 6, 2023 ... ... stocks growth stocks (according to analyst forecasts). Have feedback on this article? Concerned about the content? Get in touch with us ...Find real-time M - Macy's Inc stock quotes, company profile, news and forecasts from CNN Business.Mar. 20, 2023, 08:47 AM. SVB Securities analyst Daina Graybosch maintained a Buy rating on Nkarta ( NKTX – Research Report) today. The company’s shares opened today at $3.76. According to ...
Jun 28, 2023 · June 28, 2023 at 9:35 AM · 2 min read. Nkarta, Inc. (NKTX) has been beaten down lately with too much selling pressure. While the stock has lost 39.3% over the past four weeks, there is light at ...
Volume 525.26K. Average Volume (3M) 2.57M. Market Cap. $128.32M. Enterprise Value -$61.93M. Total Cash (Recent Filing) $280.75M. Total Debt (Recent Filing) $90.50M. Price to Earnings (P/E) -1.0. Beta 0.73.
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know Zacks - Tue Jun 7, 8:55AM CDT . The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...Valuation metrics show that Nkarta, Inc. may be fairly valued. Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of NKTX ...2.77%. $114.38M. NVAX | Complete Novavax Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nkarta Inc share price live 2.64, this page displays NASDAQ NKTX stock exchange data. View the NKTX premarket stock price ahead of the market session or assess the after hours quote. ... Raymond James Upgrades Nkarta Inc. to Strong Buy 'on Pivot to Autoimmune and AML Outlook' (Updated - October 17, 2023 3:19 PM EDT) Analysts at …In December 2022, Nkarta had US$352m in cash, and was debt-free. Looking at the last year, the company burnt through US$104m. So it had a cash runway of about 3.4 years from December 2022. There's ...
Find the latest SEC Filings data for Nkarta, Inc. Common Stock (NKTX) at Nasdaq.com.
At the forefront of its drug development, the company is advancing clinical studies of lead cancer vaccine candidate, IO102-IO103, currently being assessed in several programs. The most recent update caused a bit of a stir. Shares tanked by 25% in a single session yesterday after IO said it has now randomized 225 patients into the global Phase ...
Company Summary. Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which ...The consensus price target of analysts on Wall Street is $14.13, which implies an increase of 80.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $25.00 respectively. As a result, NKTX is trading at a discount of -819.12% off the target high and -230.88% off the low.Nov 28, 2023 · It has underperformed other stocks in the Biotechnology industry by 0.45 percentage points. Nkarta stock is currently +97.66% from its 52-week low of $1.28, and -72.62% from its 52-week high of $9.24. As of Nov 20, 2023, there are 49.07M shares of NKTX outstanding. The market cap of NKTX is $124.15M. In the past 24 hours, 524,249 NKTX shares ... NKTX : Nkarta stock forecast by Wall Street Analysts. The average Nkarta stock forecast from last 6 month is $14.5, and this show a -37.64% decrease in average from the prior price target of the each prediction. Also, this average forecast of $14.5 represents a -42.98% decrease from the past average forecast of $25.43, 6 months ago …Nkarta, Inc. (NKTX) stock forecast and price target. Find the latest Nkarta, Inc. NKTX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.
Apr 25, 2022 · All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ... Analyst projections state that NKTX is forecast to be at a low of $10.00 and a high of $25.00. In order for the stock price to hit the forecast high, the stock would need to plunge -972.96% from its current level, while the stock would need to crash -329.18% from its current level to reach the projected low. Nkarta Inc (NKTX) estimates and ...Is Nkarta Stock Undervalued? The current Nkarta share price is $2.30. The Score for NKTX is 49, which is 2% below its historic median score of 50, and infers higher risk than normal. NKTX is currently trading in the 40-50% percentile range relative to its historical Stock Score levels. Find the latest Gamida Cell Ltd. (GMDA) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Performance Outlook. Short Term. 2W - 6W. Mid ...$ 1.898326 1-Month Prediction $ 1.713021 3-Month Prediction Unlock 6-Month Prediction Unlock 1-Year Prediction Unlock Loading... According to our current NKTX stock …Wall Street Stock Market & Finance report, prediction for the future: You'll find the Enbridge share forecasts, stock quote and buy / sell signals below. According to present data Enbridge's ENB shares and potentially its market environment have been in bearish cycle last 12 months (if exists).May-25-21 07:30AM. Nkarta Announces June 2021 Investor Conference Schedule. (GlobeNewswire) -6.32%. Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials ...
1.43. -0.05. -3.72%. Get Nkarta Inc (NKTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.
Competitors. Stock Price Forecast. The 17 analysts offering 12-month price forecasts for Livent Corp have a median target of 24.00, with a high estimate of 38.00 and a low estimate of 15.00. The ...Chief Financial & Business Officer exercised options and sold US$71k worth of stock Jul 28. Nkarta, Inc. Announces Executive Changes Jul 26. Price target …However, the unknown biotech stock holds value at current levels. With some promising developments, NKTX stock is likely to surge in 2023. For clinical-stage biotechnology companies, financing ...Apr 25, 2022 · On March 17, the company reported an earnings loss of 69 cents per share, which did beat the Thomson Reuters forecast of a loss of 75 cents. Research analysts expect Nkarta will post a loss of $3. ... In 2022, GSK plc's revenue was 29.32 billion, an increase of 18.74% compared to the previous year's 24.70 billion. Earnings were 14.96 billion, an increase of 241.07%. Financial numbers in GBP Financial Statements.Oct. 17, 2023, 07:24 AM. (RTTNews) - Biopharmaceutical company Nkarta, Inc. (NKTX) announced Tuesday the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug ...When Nkarta last reported its balance sheet in June 2022, it had zero debt and cash worth US$413m. Looking at the last year, the company burnt through US$78m. That means it had a cash runway of ...
Nkarta (NKTX) Company Description: Nkarta Inc is a bio-pharmaceutical company focused on the discovery, development and commercialization of engineered, allogeneic, and off-the-shelf cell ...
Nkarta's earnings are forecast to decline at 9.2% per annum while its annual revenue is expected to grow at 77.8% per year. EPS is expected to grow by 7.3% per annum.
Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Nkarta has an average ...Analysts have provided the following ratings for Nkarta (NASDAQ:NKTX) within the last quarter: According to 5 analyst offering 12-month price targets in the last 3 months, Nkarta has an average ...Stock Price Forecast. According to 5 stock analysts, the average 12-month stock price forecast for Nkarta stock is $13, which predicts an increase of 392.42%. …Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...NKTX | Oversold Healthcare Play | LONG Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p Nkarta, Inc., a a clinical-stage biopharmaceutical ...Dec 2, 2023 · The consensus price target of analysts on Wall Street is $14.13, which implies an increase of 80.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9.00 and $25.00 respectively. As a result, NKTX is trading at a discount of -819.12% off the target high and -230.88% off the low. NKTX | Oversold Healthcare Play | LONG Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p Nkarta, Inc., a a clinical-stage biopharmaceutical ... Amazon Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 42 stock analysts, the average 12-month stock price forecast for Amazon stock is $170.76, which predicts an increase of 16.14%. The lowest target is $116 and the highest is $230. On average, analysts rate Amazon stock as a strong buy.IOBT Stock 12 Months Forecast. $9.00. (837.99% Upside) Based on 3 Wall Street analysts offering 12 month price targets for IO Biotech in the last 3 months. The average price target is $9.00 with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 837.99% change from the last price of $0.96.
Jun 15, 2023 · (See NKTX stock forecast) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Penny Stock Screener. Disclaimer: The opinions expressed in this article are ... About the Nkarta, Inc. stock forecast. As of 2023 October 17, Tuesday current price of NKTX stock is 1.495$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). Nkarta, Inc. (NKTX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. See Nkarta, Inc. (NKTX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Dec 1, 2023 · Valuation metrics show that Nkarta, Inc. may be fairly valued. Its Value Score of C indicates it would be a neutral pick for value investors. The financial health and growth prospects of NKTX ... Instagram:https://instagram. best coursera coding coursesaapl stock price predictioncheck real goldis trading forex legal Wall Street Stock Market & Finance report, prediction for the future: You'll find the Seven Arts Entertainment share forecasts, stock quote and buy / sell signals below. According to present data Seven Arts Entertainment's SAPX shares and potentially its market environment have been in bearish cycle last 12 months (if exists). pdi dividend historynaut stock M Stock 12 Months Forecast. Based on 14 Wall Street analysts offering 12 month price targets for Macy's in the last 3 months. The average price target is $14.83 with a high forecast of $19.00 and a low forecast of $10.00. The average price target represents a -0.07% change from the last price of $14.84.Nkarta Inc (NKTX) Company Description. Nkarta Inc is a biopharmaceutical company developing engineered natural killer (NK) cells to fight cancer. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. trading futures for beginners Dec 1, 2023 · The Nkarta Inc. stock price gained 1.16% on the last trading day (Friday, 24th Nov 2023), rising from $2.59 to $2.62. During the last trading day the stock fluctuated 3.53% from a day low at $2.55 to a day high of $2.64. The price has risen in 6 of the last 10 days and is up by 27.8% over the past 2 weeks. Volume fell on the last day by -163 ... M Stock 12 Months Forecast. Based on 14 Wall Street analysts offering 12 month price targets for Macy's in the last 3 months. The average price target is $14.83 with a high forecast of $19.00 and a low forecast of $10.00. The average price target represents a -0.07% change from the last price of $14.84.